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ABSTRACT 
Bone joints are the junctions between bones in the body which link the skeletal system into a functional whole. A joint may be the connecting 
point between two or more bones. Overtime, as people age or due to lifestyle or genetic factors, they may experience diseases and pains in the 
joints. Conventional treatment options for bone and joint diseases, pain and inflammation have a number of drawbacks that obstruct op timal 
treatment of the disease. Various other treatment methods and formulations have been investigated to remove these drawbacks. Microspheres 
are one of the most interesting and attractive approaches to eliminate these limitations. In recent years, prolonged release microspheres have 
been developed and explored as a viable method for delivery of drugs to the bones and joints. Local delivery of drugs to the affected bone or 
joint offers many advantages over traditional treatment methods including- better therapeutic response, lesser required dose of drug, lesser 
chances of wastage of drug, better absorption of drug in the diseased site, lesser chances of side effects etc. The objective of this review is to 
explore the field of drug delivery to bone joints, various methods of development of drug-loaded microspheres, factors that influence the 
release of drug from the microspheres as well as the types of hurdles faced in their preparation. 
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INTRODUCTION 
Joint pain and inflammation affects a major portion of 
society and has been recognized by medical organizations as 
one of the leading causes of disabilities in elderly patients. 
Though it is difficult to completely treat the causative 
diseases such as arthritis and no foolproof cure has been 
found yet1, it is possible to relieve the painful symptoms 
using certain medications. Intra-articular (IA) injections of 
these drugs offers advantages that are not possible through 
conventional methods of drug administration.2 However, the 
therapeutic potential of IA injections is severely restricted 
due to the rapid clearance of the drugs from the injected 
site.3 Current treatment strategies are focused on short-term 
relief from symptoms but ultimately cannot replace surgical 
procedures. Nonetheless, treatment and suppression of pain 
and inflammation related symptoms are a major component 
of the overall therapy process. In this study, we look into the 
extents of joint pain and inflammation and the current 
medical procedures adopted to treat them. The possibility of 
the use of microspheres as a drug delivery device for the 
treatment of symptoms has also been discussed along with 
the research and advances done in the field and the 
challenges faced in the use of microspheres for treatment of 
joint pain and inflammation. 
Joint pain and inflammation-  
Joints in the skeletal system are junctions or connecting 
links between two or more bones. A joint consists of 
different parts namely- Cartilage (tissue that covers the 
surface of a bone at a joint. Cartilage helps reduce the 
friction of movement within a joint.); Synovial membrane 
(this tissue lines the joints and seals it into a joint capsule. It 
secretes a clear, sticky fluid around the joint to lubricate it); 
Bursas (fluid-filled sacs between bones, ligaments that help 
cushion the friction between joints), Tendons, Femur, Tibia, 
Patella etc.4 Inflammation and pain-related diseases of the 
bone joints are a common disease plaguing the society today. 
Joint pain and inflammation can occur due to swelling in the 
synovial membrane or increase in the volume of synovial 
fluid which leads to accumulation of inflammatory material 
in and around the joint.5 This adds to the swelling. As the 
disease progresses, structural changes within the joint 
amplify the sensation of pain as well as inflammation. Unless 
treated, these can quickly develop into more serious 
underlying complications such as osteoarthritis, rheumatoid 
arthritis, bursitis etc. and cause physical disability. 
According to arthritis.org, osteoarthritis affects 31 million 
people in the U.S. alone and by the year 2040, 78 million 
people would be diagnosed with arthritis.6 Several diseases 
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are associated with joint pain and inflammation including 
osteophytes and bone cysts formation, degeneration of 
cartilage on the surface of a bone at a joint, synovial 
membrane inflammation, peri-articular bone reaction etc.7 
Drug therapy-  
Commonly, joint pain and inflammation are treated and 
managed by oral or topical administration of an NSAID, 
acetaminophen or Hyaluronic acid injection.8 Opioids, anti-
depressants and neuromodulators have also been 
investigated for their efficacy in treating these conditions 
but no strong evidence is available.9 In severe cases, when 
the disease has not responded to conventional methods of 
treatment, surgery may be the only option left which may 
involve total joint replacement. 
For the purpose of temporary pain and inflammation 
management, oral NSAIDs are preferred and frequently 
used.10 Diclofenac is one of the few selective non-steroidal 
anti-inflammatory drugs used for suppression of pain and 
inflammation in the joints. Its efficacy in treatment of pain 
associated with joint disorders has already been 
established.11 Diclofenac is a non-selective NSAID i.e. it 
inhibits the functioning of both COX-1 and COX-2 which are 
responsible for the expression of prostaglandins (pro-
inflammatory mediators).12 Several other NSAIDs are also 
used for the management of joint pain and inflammation 
including- celecoxib, ibuprofen, naproxen, piroxicam etc. 
which have their own upsides and limitations. Previous 
studies have also indicated the relatively better performance 
of diclofenac as well as its safety and tolerability when 
compared to other NSAIDs.13,14,15 Diclofenac, however, has 
its own set of side effects which include- blood dyscrasias, 
anaphylaxis, gastrointestinal bleeding, gastric ulcers etc.16 
These might prove to be life-threatening which limits the 
long term use of NSAIDs in chronic conditions such as 
Osteoarthritis. This necessitates localized delivery of the 
drug and in a sustained/prolonged manner so that the 
corresponding side effects are prevented as well as the 
therapeutic effect of drug is secured for a longer period of 
time than conventional methods of drug delivery. 
Local drug delivery and microspheres-  
It is well understood that conventional methods of drug 
delivery have certain disadvantages which can be improved 
upon. A local drug delivery system (DDS) is, therefore, 
necessary which can deliver the drug at or to the diseased 
site, overcome the side effects related to systemic and 
conventional delivery methods and also facilitate prolonged 
release of drug in small but required quantities at the 
diseased site. Other desirable features in the DDS include its 
biocompatibility and biodegradability at the administration 
site without causing any toxicity, irritation or side effects 
and its ability to enhance the residence time of drug at the 
diseased site. 
A diverse set of formulations and DDS have been 
investigated for this purpose. One of the most suitable and 
appealing candidates has been found to be microspheres. 
Besides satisfying the aforementioned requirements, 
microspheres offer other added advantages including a 
controlled or pulsatile release of drug, protection of drug 
from degradative enzymes and chemicals within the body, 
increased patient compliance due to reduced frequency of 
drug intake.17 
Polymeric microspheres are one of the ideal carriers for the 
purpose of several controlled delivery implementations as 
they are capable of microencapsulating various types of 
drugs (including small molecules, proteins and nucleic 
acids), are biocompatible, provide high bioavailability and 
promote slow release of drug over a lengthy period of time. 
These are also easily administrable through a syringe needle. 
The use of polymeric microspheres for diagnostic, 
therapeutic and other medical applications has grown 
manifold in recent years. These have been investigated for 
controlled release and stability of vaccines18, stabilization of 
protein therapeutics19, safe and efficient DNA delivery for 
gene therapy20, tumor targeting and embolization of 
tumors21 etc. Microspheres have also been developed and 
assessed for localized delivery of drugs to the bones and 
joints for diagnosis as well as treatment of various diseases 
and infections.22,23,24 
Microspheres for clinical applications are strictly regulated 
for their shape and size as well as their release pattern 
within the body along with their degradation behavior so as 
to avoid any chances of critical complications after their 
administration. However, this drug delivery system suffers 
from its own set of limitations including- difficulty in large-
scale manufacturing, difficulty in controlling the release rate 
of drug, potential inactivation/degradation of drug during 
formulation, differences in release rate from one dose to 
another (which may depend upon other uncontrollable 
factors), burst release of drug or release of whole dose of 
drug inside the body due to a defective formulation can 
cause toxicity and prove to be fatal.25,26,27 
SOME RELEVANT METHODS/TECHNIQUES FOR 
PREPARATION OF MICROSPHERES FOR PURPOSE 
OF DELIVERY TO THE BONE JOINTS 
Solvent Evaporation technique:  
This method of preparation of microspheres involves the 
dissolution of polymer in a water-immiscible organic solvent 
following which the drug is dispersed or dissolved into the 
polymer-solvent solution. This solution is then emulsified in 
an excess amount of aqueous or continuous phase. 
Microspheres are formed by the diffusion of the organic 
solvent into the continuous phase and its subsequent 
evaporation from the air/water interface.28,29 
Emulsion cross-linking method:  
In this method, weighed quantities of polymer and drug are 
dissolved in a suitable organic solvent. This drug-polymer 
solution is then added to an adequate quantity of oleaginous 
vehicle (eg-liquid paraffin) containing a surfactant. The 
resulting mixture is stirred continuously for 2 hours, after 
addition of an aqueous solution of cross-linking agent, to 
obtain a dispersion of microspheres in paraffin oil. The 
microspheres are allowed to settle due to gravity and the 
supernatant is decanted. The residual microspheres are 
filtered and washed with n-hexane to remove the oil.30,31 
Spray-drying technique:  
A polymer solution is first prepared by dissolution of the 
polymer in a suitable organic solvent such as acetone, 
ethanol, dichloromethane etc. The selected drug is then 
uniformly dispersed in the polymer solution with the help of 
a homogenizer. Consecutively, spray drying of the above 
solution is performed using a spray drier with a standard 
nozzle. When the solution is supplied to the nozzle with a 
peristaltic pump, atomization takes place and small droplets 
are produced. The droplets along with hot air are blown into 
a chamber where the droplets are evaporated and the dry 
product (microspheres) are obtained.32,33 
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Solid-in-oil-in-water (S/O/W) multi-emulsion process:  
A suspension of drug is dispersed in the polymer solution 
dissolved in a volatile organic solvent. The resulting solution 
is stirred at high speed for 1 minute and then added to 
gelatin solution to form an emulsion. A high speed 
homogenizer is used to prepare multi-emulsion. The 
resulting emulsion is continuously stirred at room 
temperature until the solvent is evaporated which results in 
the formation of solidified microspheres. These are 
recovered by centrifugation and washed with distilled 
water.34,35 
Ionotropic gelation technique:  
This technique is based on the principle of coalescence of 
colloidal particles of polymer. The ionotropic gelation of 
calcium chloride ions with the oppositely charged (anionic) 
polysaccharide sodium alginate results in the formation of 
microspheres. Subsequently, the colloidal polymer particles 
are fused into a homogenous matrix. The polymer particles 
coalesce during the drying process and form a homogenous 
film.36,37,38 
Coacervation method:  
This process involves the distinction of a macro-molecular 
solution into two immiscible phases- a dense coacervate 
phase (concentrated with macromolecules) and a dilute 
equilibrium phase. Simple coacervation is actuated by 
several factors such as temperature change, addition of 
micro-ions which cause dehydration of macromolecules 
because they favor polymer-polymer interactions over 
polymer-solvent interactions. Microspheres with specific 
properties can be prepared by manipulation of such 
parameters.39,40 Complex coacervation method has also been 
utilized for the formulation of microspheres intended for 
intra-articular delivery. 
 
Interfacial polymerization methods: 
i. Suspension polymerization- A solution of monomer 
and an initiator is prepared in a suitable solvent. This 
solvent is added to a suspension in which the monomer 
and initiator are insoluble. The mixture is then 
subjected to agitation, in presence of low molecular 
weight polymers or surfactants, which results in the 
formation of solvent droplets. Polymerization occurs in 
the solvent droplets and the polymer takes the shape 
and size of the droplets resulting in the formation of 
microspheres.41,42 
ii. Emulsion polymerization- In this method, an initiator 
is dissolved in a solution containing emulsifiers and 
stabilizing molecules. The use of dispersing agents 
results in the formation of micelles with monomers. 
This method can be used for encapsulating drug within 
the microspheres or their adsorption on the surface of 
the microspheres.43,44 
iii. Dispersion polymerization- This technique is also 
referred to as phase-separation polymerization.45 A 
solution mixture of monomer, initiator and polymeric 
stabilizer is prepared where polymerization takes 
place. Thereafter, the polymer chain grows until it 
precipitates forming nano-sized particles which can be 
induced to aggregate and form larger particles in the 
size range 1-20µm.46,47 
Double emulsion technique: This process of microsphere 
preparation is suitable for water soluble drugs, proteins, 
peptides and vaccines and involves the formation of double 
emulsion (w/o/w). In this method, a continuous phase 
containing the polymer solution is prepared. After 
homogenization or sonication of this primary emulsion, an 
aqueous solution of polyvinyl alcohol (PVA) is added which 
forms a double emulsion. The emulsion is then treated with 
solvent removal by evaporation or extraction.48,49 
 
Table 1: Drugs encapsulated microspheres for treatment of skeletal disorders 
Method of 
preparation 
Material/ Polymer Drug Administration site Application Ref. 
Solvent 
evaporation 
PLGA Simvastatin Rabbit calvaria 
critical-size defect 
Bone formation 50 
w/o/w double 
emulsion 
technique 
PLGA/ 
hydroxyapatite 
Simvastatin Middle shaft of the 
tibia 
Bone regeneration 51 
Single emulsion 
solvent 
evaporation 
PLGA Melatonin In-vitro study Bone healing 52 
Solvent 
evaporation 
PLGA Sodium alendronate In-vitro study Bone repair 53 
w/o/w double 
emulsion 
technique 
PLLA-PEG-PLLA tri-
block copolymer 
Nanosilver Rat cranium critical-
size defect 
Bone regeneration 54 
Emulsion cross-
linking 
Paselli (II) Meclofenamic 
Sodium 
In-vitro study Bone tissue engineering 55 
Emulsion cross-
linking 
Chitosan Celecoxib In-vitro study Bone healing 56 
Spray-drying Chitosan/ Pectin Ciprofloxacin 
hydrochloride 
Anteromedial 
incision on proximal 
tibia 
Treatment of 
Osteomyelitis 
32 
Spray-drying Bovine serum 
albumin 
Dexamethasone In-vitro study Treatment of ankylosing 
spondylitits, osteo/ 
rheumatoid arthritis 
57 
s/o/w multi-
emulsion 
technique 
PLGA Lornoxicam Left knee joint of 
New Zealand white 
rabbits 
Treatment of 
Osteoarthritis 
35 
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Ionotropic 
gelation 
Chitosan, Gelatin B Tramadol 
hydrochloride 
In-vitro study Treatment of arthritis, 
arthralgia 
58 
Ionotropic 
gelation 
Eudragit S100, 
Sodium Alginate 
Diclofenac Sodium In-vitro study Treatment of arthritis 37 
Complex 
coacervation 
Gelatin Chondroitin-6-
Sulfate 
Mouse knee joints Treatment of 
Rheumatoid/ 
Osteoarthritis 
59 
Suspension 
polymerization 
PMMA Hydrogel collagen In-vitro study Bone tissue engineering 60 
Emulsion 
polymerization 
Polystyrene/PMMA Doxorubicin In-vitro study Bone repair 61 
Dispersion 
polymerization 
Coralline 
hydroxyapatite/ 
Gelatin 
Gentamicin In-vitro study Bone healing 62 
 
Yoshihito et. al. prepared poly(lactic-co-glycolic acid) (PLGA) 
microspheres incorporated with simvastatin (SIM) by 
solvent evaporation method. SIM-loaded PLGA microspheres 
(20-30µm) showed drug content loading of 91±3.78% and 
presented a slow drug release over a period of ~1month in-
vitro. In-vivo tests in critical size defect of rabbit calvaria 
confirmed that the microspheres containing SIM were 
capable of enhancing bone formation.50 In another study, 
starch-based microspheres were formulated by emulsion 
cross-linking technique and were loaded with 
meclofenamate sodium. With minor alterations in certain 
parameters, this technique allowed for controlled formation 
of microspheres ranging from 3-540µm. The release pattern 
from these microspheres was checked in-vitro in two 
different pH mediums. It was concluded that drug release 
from the microspheres was very fast in the initial 2 hours 
irrespective of the pH medium used and ionic concentration 
of the medium strongly influenced drug release.55 
Lornoxicam (Lnxc) encapsulated PLGA microspheres 
(7.47µm) were prepared by a process involving s/o/w 
emulsion and showed controlled release of ~80% of drug 
over a period of 1 month. Drug retention was examined in 
the synovial fluid in rats and it was determined that intra-
articular administration of Lnxc-loaded PLGA microspheres 
enhanced drug targeting in the joint cavity due to prolonged 
residence time of drug in the joint.35 Microspheres 
containing diclofenac sodium were prepared by ionotropic 
gelation technique using Eudragit S100 and Sodium alginate 
as the encapsulating agents. The microspheres exhibited 
sustained release of drug over a period of 12 hours in-vitro.37 
FACTORS INFLUENCING RELEASE OF DRUG FROM 
MICROSPHERES: 
The method or technique employed for preparation of 
microspheres plays an important role in drug 
encapsulation and its release kinetics. Thakkar et.al., in their 
study, observed that heat cross-linked microspheres 
released drug at a much faster rate than chemically cross-
linked microspheres.56 Furthermore, a variety of other 
factors including- the type of polymer used, molecular 
weight of the polymer, amount of polymer, copolymer 
composition, excipients used, size of the microspheres 
produced, nature of the dissolution medium etc. also 
influence the release rate of drug from the microsphere 
formulation.17 
The choice of polymer and its degradation mechanism 
affects release rates of the drug. On the basis of hydrolysis 
rates of the polymers, they can be classified as- surface-
eroding and bulk-eroding.63 Bulk-eroding polymers (eg- 
PLG) generally degrade at a much faster rate and cause a 
burst release of the drug initially. Subsequently, release rate 
of the drug is sustained.28 However, it is difficult to control 
drug release in case of bulk-eroding polymers. On the other 
hand, polymers that are surface-eroding (eg- 
Polyanhydrides) exhibit uniform degradation at the surface, 
usually at a constant rate and as such drug is also released in 
a controlled manner.64,65 
Molecular weight of the polymer also influences drug 
release pattern. It has been observed that higher molecular 
weight polymers have decreased permeability and slower 
drug release rates.19,66,67 As the amount of polymer for 
encapsulation is increased, a thicker 
membrane/barrier/coating is formed around the drug core 
which decreases release rate of the drug.68 
Copolymers consist of co-monomers in varying ratios which 
also affect drug release rates. Copolymers composed of 
rapidly degrading monomers in higher ratios tend to release 
drug at a faster rate than copolymers with higher 
concentration of slowly degrading monomers.69,70 
Nonetheless, it has been observed that the effect of 
copolymer composition on drug release can be influenced by 
phase behavior of the copolymer and thermal properties of 
the drug.71 
Exipients used in the formulation of microspheres can 
also impact release rates of the drug. For example, Park et.al. 
used α-tricalcium phosphate based calcium phosphate 
cement to improve the rigidity of the protein-encapsulated 
microspheres. It was observed that incorporation of calcium 
phosphate in the formulation further sustained the release 
of the protein.22 To enhance the stability of myoglobin-
encapsulated PLGA micropsheres, Rhodes et.al. prepared the 
formulation using mannitol as a stabilizer. Mannitol was 
reported to increase the release rate by increasing the 
porosity of the microspheres.72 
It has also been found that parameters related to 
dissolution medium such as its pH, temperature, buffer 
composition etc. also influence drug release rates.73 Size of 
the microspheres has also been investigated and found to 
affect drug release.74 
CHALLENGES/CONSIDERATIONS IN FABRICATION 
OF MICROSPHERES FOR DRUG DELIVERY TO BONE 
JOINTS 
Although a suitable and interesting approach in the 
treatment of joint diseases, certain challenges come to the 
forefront which much be first taken care of. Some have been 
explained below. 
Difficulty arises in maintaining uniform particle size of 
microspheres during/after formulation process. Size varies 
considerably ranging from a few nanometers to over 100 
micrometers. Variance in size causes difference in release 
kinetics and statistics. This would result in infrequent and 
uncontrolled drug release. Butoescu et.al. reported that ideal 
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size of microspheres for intra-articular delivery should 
range between 5-10µm.75 Smaller-sized microspheres can be 
easily uptaken by synoviocytes76 whereas larger-sized 
microspheres release drug at a slower rate and may elicit a 
giant cell response. Liggins et.al. discovered that along with 
size, shape of the particles also influenced their efficacy in 
the treatment of joint diseases and disorders. Spherical 
particles are better suited for intra-articular delivery.77 
Biocompatibility of the drug and polymer in the joint is of 
paramount importance. Polymers such as Poly (lactic acid) 
(PLA), Poly (glycolic acid) (PGA), Poly (lactic co-glycolic 
acid) (PLGA) are generally accounted as safe and 
biocompatible but upon breakdown, lower the pH in the 
surrounding tissues which can adversely affect the effect of 
the drug and further worsen inflammation symptoms.78 
CONCLUSION 
Joint diseases and disorders are troublesome conditions that 
torment a significant percentage of population today. 
Normal movement for patients becomes a tiresome and 
painful task. Conventional drug therapies were developed 
but these suffer from limitations which in some cases even 
outweigh the benefits. As such, novel drug delivery systems 
have been investigated and developed and are still being 
optimized to this day in the quest of an ideal drug delivery 
system which hopefully undermines all the limitations 
related to drug delivery to the bone joints. Microspheres are 
one of the most sought-after and researched formulations 
for this purpose. These are being investigated for not only 
drug delivery to the bones and joints but also tumours, 
brains and other vital organs and tissues of the body. 
Although these have numerous benefits over traditional 
systems, there still are some challenges which have to be 
considered in their formulation.  New techniques and 
methods of microsphere preparation are emerging with 
newer features and the field is continually evolving and 
growing at a fast pace. 
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